These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25563210)

  • 1. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.
    Brod M; Adler LA; Lipsius S; Tanaka Y; Heinloth AN; Upadhyaya H
    Atten Defic Hyperact Disord; 2015 Jun; 7(2):141-50. PubMed ID: 25563210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL).
    Matza LS; Johnston JA; Faries DE; Malley KG; Brod M
    Qual Life Res; 2007 Nov; 16(9):1511-20. PubMed ID: 17874207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.
    Bushe C; Sobanski E; Coghill D; Berggren L; De Bruyckere K; Leppämäki S
    CNS Drugs; 2016 Apr; 30(4):317-34. PubMed ID: 27055440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
    Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the adult ADHD investigator symptom rating scale (AISRS).
    Spencer TJ; Adler LA; Meihua Qiao ; Saylor KE; Brown TE; Holdnack JA; Schuh KJ; Trzepacz PT; Kelsey DK
    J Atten Disord; 2010 Jul; 14(1):57-68. PubMed ID: 19794135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
    Thome J; Dittmann RW; Greenhill LL; Lipsius S; Tanaka Y; Bushe C; Escobar R; Heinloth AN; Upadhyaya H
    Atten Defic Hyperact Disord; 2017 Dec; 9(4):219-229. PubMed ID: 28477289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study.
    Tanaka Y; Escobar R; Upadhyaya HP
    Atten Defic Hyperact Disord; 2017 Jun; 9(2):113-120. PubMed ID: 28058589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.
    Asherson P; Bushe C; Saylor K; Tanaka Y; Deberdt W; Upadhyaya H
    J Psychopharmacol; 2014 Sep; 28(9):837-46. PubMed ID: 25035246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
    Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
    CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
    Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
    Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
    Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis.
    Robison RJ; Reimherr FW; Marchant BK; Faraone SV; Adler LA; West SA
    J Clin Psychiatry; 2008 Feb; 69(2):213-21. PubMed ID: 18211131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.
    Saylor K; Buermeyer C; Sutton V; Faries D; Khan S; Schuh K
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):831-42. PubMed ID: 18315454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
    Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
    BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
    Manor I; Ben-Hayun R; Aharon-Peretz J; Salomy D; Weizman A; Daniely Y; Megiddo D; Newcorn JH; Biederman J; Adler LA
    J Clin Psychiatry; 2012 Dec; 73(12):1517-23. PubMed ID: 23290324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.